Japan Pharmas Seek Advantages In High Hay Fever Season
This article was originally published in PharmAsia News
Executive Summary
Japanese drug makers seek to expand their lines of hay fever drugs to take advantage of a heavy season for the ailment by offering year-round offshoots. Some firms are emphasizing protection against house dust and pollen from a Japanese cypress while others seek to make over-the-counter versions of prescription drugs. The pollen count in Japan this spring is projected to be as much as 200 percent higher than last year in parts of the country. (Click here for more - a subscription may be required
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.